HCAR2 and breast cancer: Furthermore, in vivo studies have also demonstrated that the activation of HCAR2, with niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis [86,87], while deletion of HCAR2 increased tumor incidence of spontaneous breast cancer in transgenic mice [83].